VIVUS Earnings: Here’s Why Investors Don’t Like These Results

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

VIVUS Inc. (NASDAQ:VVUS) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 5.15%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

VIVUS Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.53 in the quarter versus EPS of $-0.20 in the year-earlier quarter.

Revenue: Was the same at $4.11 million as the year-earlier quarter.

Actual vs. Wall St. Expectations: VIVUS Inc. reported adjusted EPS loss of $0.53 per share. By that measure, the company missed the mean analyst estimate of $-0.51. It missed the average revenue estimate of $5.22 million.

Quoting Management: “The FDA’s approval of the REMS modification allowing distribution of Qsymia through certified retail pharmacy locations was a significant achievement in our ongoing efforts to expand access to Qsymia,” stated Leland Wilson, chief executive officer of VIVUS. “We have begun to lay the foundation and our team is working diligently to ensure availability of Qsymia in certified retail pharmacies.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business